Vaxcyte, Inc.
PCVX
$59.44
-$0.92-1.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.00% | 1.26% | 12.85% | 41.15% | 49.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.84% | 91.30% | 69.13% | 73.22% | 47.87% |
| Operating Income | -33.84% | -91.30% | -69.13% | -73.22% | -47.87% |
| Income Before Tax | -70.68% | -127.85% | -79.83% | -106.38% | -29.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.68% | -127.85% | -79.83% | -106.38% | -29.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.68% | -127.85% | -79.83% | -106.38% | -29.42% |
| EBIT | -33.84% | -91.30% | -69.13% | -73.22% | -47.87% |
| EBITDA | -34.22% | -92.82% | -67.47% | -73.25% | -47.29% |
| EPS Basic | -60.69% | -121.63% | -78.20% | -87.44% | -11.56% |
| Normalized Basic EPS | -60.68% | -121.60% | -78.21% | -87.43% | -11.56% |
| EPS Diluted | -60.69% | -121.63% | -78.20% | -87.44% | -11.56% |
| Normalized Diluted EPS | -60.68% | -121.60% | -78.21% | -87.43% | -11.56% |
| Average Basic Shares Outstanding | 6.22% | 2.81% | 0.91% | 10.11% | 16.01% |
| Average Diluted Shares Outstanding | 6.22% | 2.81% | 0.91% | 10.11% | 16.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |